Press Releases & Alerts

October 13, 2011
Proventys and inVentiv Medical Management Form Collaboration to Deliver a New Standard in Evidence-Based Oncology Care Management Programs
Proventys CDS Oncology™ Powered By NCCN® to Provide inVentiv Medical Management's Physicians and Care Managers with Efficient Access to Advanced Decision Support Technology and the World's Leading Oncology Practice Guidelines Download PDF

February 02, 2012
McKesson Corporation Acquires Proventys’ Advanced Decision Support Assets in Oncology
Proventys, a leading developer of personalized decision support technologies for oncology and cardiology, announced that McKesson Corporation has acquired its CDS Oncology assets. “Proventys is very proud of the innovative offerings we developed to advance cancer care through the use of smart technologies that facilitate more personalized, evidence-based treatment for patients,” said Ralph Snyderman, MD, Proventys’ founder and chairman. Proventys was founded to support the ability of physicians to deliver personalized medicine at the point of clinical care. The Company created software-based predictive and prognostic tests (PDx), including one to assess adverse outcomes of cancer chemotherapy. It also developed a state-of-the-art clinical decision support system (CDS), in collaboration with the National Comprehensive Cancer Network (NCCN), to provide the best standards of care for patients with cancer. About Proventys Proventys is a healthcare technology company that provides innovative decision support solutions to help clinicians optimize care for patients on a personalized basis. The Company developed a novel, web-based decision support system that dynamically renders guidelines, customizable clinical pathways and payer-specific coverage policies, presenting clinicians with relevant treatment options based on individual patient characteristics. In addition, the Company pioneered the creation of software-based predictive tests (PDx) to help clinicians assess a patient’s personalized risk of a specific clinical event and guide appropriate care decisions. The Company’s first PDx product candidate, currently under FDA review (de novo), was designed to help oncologists assess a patient’s risk of febrile neutropenia, a common and serious complication of chemotherapy. Proventys is dedicated to aligning the interests of patients, providers and payers by offering solutions that personalize care and improve outcomes. # # # Contact: G. Steven Burrill Burrill & Company burrill@b-c.com (415) 591-5400 Download PDF

October 06, 2010
Proventys To Unveil Advanced Decision Support Technology At The National Comprehensive Cancer Network's (NCCN) Hematologic Malignancies Conference
Proventys CDS Oncology™ Powered By NCCN®, Will Be Featured At Booth #24 Download PDF

July 26, 2010
National Comprehensive Cancer Network (NCCN) and Proventys Collaborate to Enhance Quality and Efficiency in Cancer Care
Collaboration Integrates Evidence-Based Medicine and Innovative Decision Support Technologies, Providing Clinicians Access to the NCCN Guidelines at the Point of Care Download PDF

May 22, 2009
Proventys to Unveil Clinical Research Evaluating Its Predictive Technology Platform at 2009 American Medical Informatics Association Spring Congress
Poster Presentations Explore Value and Efficiency of Clinical Decision Support Software and Embedded Multivariate Predictive Model in Enhancing Patient Care Download PDF

May 01, 2009
Proventys Appoints Surya Singh, M.D., as Chief Medical Officer and Vice President of Clinical Development
Dr. Singh Brings Extensive Expertise in Predictive Medicine and Developing Innovative Healthcare Solutions Download PDF

May 01, 2009
Proventys Poised to Improve Delivery of Care Through Personalized, Predictive Technologies
Company’s Unique Vision Validated by $8 Million Investment Led by Burrill & Company to Fuel Company’s Innovative Point-of-Care Solutions Download PDF

November 13, 2008
Dr. Ralph Snyderman Receives Lifetime Achievement Award for Contributions to Prospective and Personalized Health Care
Frost & Sullivan Honors Dr Snyderman at 2008 Excellence in Healthcare Innovation Awards Banquet Download PDF

May 14, 2008
Proventys Closes $5.65M in Series A1 Funding; Announces New CEO
Download PDF

February 20, 2008
McKesson Advances Personalized Medicine Strategy with Proventys Agreement
Download PDF

November 29, 2007
Dr. Snyderman Receives the 2007 Leadership in Personalized Medicine Award
Presented at the Harvard Personalized Medicine Conference Download PDF